Thus, the study does not fully confirm the findings of an earlier report that FGFR1-amplified BC was associated with poorer OS in the overall cohort and that FGFR1 amplification was predictive of poor DFS, OS, and DMFS in ER-positive patients with BC [13]. The gene discussed is FGFR1; the disease is breast cancer.